Afleveringen
-
In this episode, we will focus on the latest in the research on ALS. ALS remains a devastating disease, but the field is now at an inflection point with a growing pipeline of precision therapies, trial-ready sites, and a new generation of clinician scientists - yet barriers persist. There is disease heterogeneity, limited trial access for patients, and rising development costs. For an update on ALS clinical trials and the Healey ALS MyMatch program, a centralized platform that matches participants to trials, we spoke with Dr. Suma Babu. Dr. Suma Babu is an associate professor of neurology at Harvard Medical School and co-director of the Neurological Clinical Research Institute at Mass General Brigham. She was interviewed by Dr. Ryan Jacobson, an associate professor of neurology at Rush University.
Disclosure: This episode does not award CME.
-
ANA Investigates is the official podcast of the American Neurological Association, featuring conversations that highlight the latest discoveries, controversies, and trends in academic neurology. After the successful release of over 80 podcast episodes, In today's episode, we'll explore the creation and evolution of the ANA Investigates podcast since its launch in September 2019. We have the privilege of hosting four legends who were instrumental in bringing this podcast to life.
First, Dr. Adeline Goss, Assistant Professor at Highland Hospital in Oakland, California, whose background as a radio host uniquely positioned her to serve as ANA investigates Executive Producer for six years.
We are also joined by Dr. Megan Richie, Associate Professor at UCSF, and Dr. Romer Geocadin, Professor at Johns Hopkins—both of whom played central roles in shaping the podcast from its earliest days through its evolution.
Finally, we're joined by Jennifer Hurley, Education and Accreditation Manager for the American Neurological Association, who has been integral to the editing, production, and sustained success of every single episode.
Disclosures: This episode does not award CME credit.
-
Zijn er afleveringen die ontbreken?
-
The diagnosis and management of idiopathic normal pressure hydrocephalus (NPH) is evolving. However, skepticism about this diagnosis persists among neurologists based upon lack of disease specific pathology, overlap with other neurodegenerative processes, and a lack of uniform diagnostic criteria. Also, prior reports of minimal or transient improvement after treatment with an invasive procedure and lack of high-quality studies has concerned some neurologists. We are joined by 2 experts in the field of movement disorders and CSF flow – Dr. Alberto Espay and Dr. Michael Williams – to discuss advances in our understanding of idiopathic NPH, the PENS trial, and evidence still needed to convince neurologists that NPH is clinical syndrome that warrants timely evaluation and treatment.
Guest(s): Dr. Alberto Espay, Professor of Neurology at the University of Cincinnati; Dr. Michael Williams, Professor Neurology and Neurological Surgery at the University of Washington Interviewer: Dr. Kara Wyant, Clinical Associate Professor of Neurology at the University of Michigan Disclosures: Dr. Espay: Consultancies & Scientific Advisory Boards Mitsubishi Tanabe Pharma America (formerly, Neuroderm), Amneal, Acorda, Abbvie, Bial, Supernus (formerly, USWorldMeds), NeuroDiagnostics, Inc (SYNAPS Dx), Intrance Medical Systems, Inc., Merz, Praxis Precision Medicines, Citrus Health, and Herantis Pharma. Dr. Williams: I am a paid consultant to Aesculap regarding devices to treat hydrocephalus Dr. Wyant: Biovie - consulting, (NEW 8/2025) ongoing, UCB Pharma - research support, ended 6/2025, PhotoPharmics - research support, ongoing -
Last year, the FDA approved adaptive deep brain stimulation for the treatment of people with Parkinson's disease. This is a major step forward in neurology. It allows personalized therapy by adjusting deep brain stimulation settings in real-time based on an individual's brain signals.
Our guest on this episode is Dr. Helen Bronte-Stewart, the John E. Cahill Family Professor of Neurology and Director of the Human Motor Control and Neuromodulation Lab at Stanford University. Dr. Bronte-Stewart was interviewed by Dr. Karlo Lizarraga, Associate Professor of Neurology and Director of the Motor Physiology and Neuromodulation program at the University of Rochester.
Disclosures: Dr. Bronte-Stewart disclosed equity in QDG Health. Dr. Lizarraga disclosed FHC: Consulting (Course Instructor), BlueRock: Research support.
-
In this episode, we'll focus on new onset refractory status epilepticus or NORSE, and its closely related presentation, febrile and infection related epilepsy syndrome, known as FIRES. NORSE and FIRES are clinical presentations where the evidence is limited, stakes are high, and treatment often has to begin before the diagnosis is clear. They also raise broader questions about how neurology can respond to rare but catastrophic illness, including how patients, families and researchers can work together to move the field forward. For an update on NORSE and FIRES, we spoke with Dr. Howard Goodkin and Dr. Larry Hirsch. Dr. Goodkin is the Shure professor of neurology and pediatrics at University of Virginia. Dr. Larry Hirsch is a professor of neurology at Yale University. They were interviewed by Dr. Ifrah Zawar, assistant professor of neurology at the University of Virginia.
Disclosures: Dr. Hirsch has received consultation fees for advising from Ceribell, Natus, & UCB and honoraria for speaking/training from Neuropace & Natus.
-
In this episode, we'll explore emerging strategies to enhance recovery after stroke. Stroke rehabilitation has long relied on physical, occupational, and speech therapy, but advances in neuroscience are opening new opportunities to directly modulate brain networks, promote plasticity, and hopefully help patients regain function. Dr. Sean Dukelow's work focuses on neurorehabilitation and the mechanisms of recovery after stroke. He's a professor and head of Physical Medicine and Rehabilitation in the Department of Clinical Neurosciences at the University of Calgary. Dr. Dukelow was interviewed by Dr. Cheran Elangovan, vascular neurologist at University of Tennessee Health Science Center. Series 7, Episode 3
Disclosures: Dr. Dukelow serves on the advisory board for Merz and Ipsen, provides consultation for AbbVie, receives speaker fees from Merz
-
Today, we'll talk with one of the true giants of stroke neurology - Dr. Louis Caplan, Professor of Neurology at Harvard Medical School and Senior Neurologist at Beth Israel Deaconess Medical Center. For decades, Dr. Caplan has shaped how we think about stroke. He's authored an enormous body of work -- landmark papers, books, and clinical descriptions that have changed how neurologists around the world recognize and classify strokes.
But today, rather than revisiting the past, we'll ask how he sees the future - of stroke, clinical reasoning in an era of AI, and of medicine itself. Dr. Caplan was interviewed by Dr. Sarah Nelson, neurointensivist and Assistant Professor of Neurology at Tufts Medical Center. Series 7, Episode 2
Disclosures: None
-
This is episode, we'll look at a national effort to advance clinical research and patient care through artificial intelligence. AI depends on data that are large, diverse, and well-labeled -- in contrast, most clinical data are siloed, inconsistent, and biased toward certain populations. The CHoRUS Network, part of the NIH's Bridge2AI consortium, is standardizing and harmonizing data from many hospitals so they can actually be used for training machine-learning models. Dr. Eric Rosenthal is Contact PI for the CHoRUS Network, Associate Professor at Harvard Medical School, and an epileptologist, clinical neurophysiologist, and neurointensivist at Mass General Brigham. He was interviewed about CHoRUS by Dr. Masoom Desai, neurointensivist at the University of New Mexico and site PI for the CHoRUS Network. Series 7, Episode 1
Disclosures: Dr. Desai disclosed: PI- MAPS-ABI locally funded by CBRR, UNMHSC, Site PI for RAISE, RESET, SAFER-EEG, KeSETT, SHINKEI-TBI trials, Site PI for CHoRUS, Bridge2AI, Site co-PI for ICECAP and Post-ICECAP. Dr. Rosenthal disclosed: Committee service on Bridge to AI and the Curing Coma Campaign
-
The American Neurological Association's 150th Annual Meeting held in Baltimore September 13-16, 2025 was a milestone meeting celebrating 150 years of progress, discovery, advances in science, and the remarkable work of academic neurologists and neuroscientists over the past century and a half. The meeting—ANA2025—featured outstanding plenary sessions, professional development workshops, interactive lunch workshops, special interest groups, cross-cutting special interest groups, the celebrated poster hall, satellite symposia, and several opportunities to network and connect with colleagues and friends.
Dr. Michelle Johansen of Johns Hopkins University School of Medicine, immediate past chair of the ANA Education Innovation Committee, engaged with meeting attendees to learn more about their experience at ANA2025 and what they think about the ANA. Listen in as meeting attendees share their insights, meeting highlights, and enthusiasm for the ANA during Dr. Johansen's boots on the ground interactions with them. From the Presidential Symposium to the closing sessions, learn about ANA2025, the science and research shared, and the reactions of those who were in Baltimore to experience it.
-
Tune into the latest podcast from the American Neurological Association (ANA), ANA Investigates: 75 Years of NINDS. This year marks the 75th anniversary of the National Institute of Neurological Disorders and Stroke (NINDS)—an opportunity to reflect on the institute's past achievements and look ahead to the future of neurological research.
This month, ANA Investigates welcomes Dr. Walter Koroshetz, Director of NINDS, in conversation with Dr. Adeline Goss, Neurohospitalist at Highland Hospital. Dr. Koroshetz joined the institute in 2007 as Deputy Director and became Director in 2015. Before joining the NINDS, he served as Vice Chair of Neurology, Director of Stroke and Neurointensive Care Services at Massachusetts General Hospital, and neurologist in the MGH Huntington's Disease Clinic.
Tune in as they discuss highlights from the NINDS's 75-year history and explore what lies ahead for neurological research and innovation.
Guest: Walter J. Koroshetz, MD, FANA Director National Institute of Neurological Disorders and Stroke Interviewer: Adeline Goss, MD Neurohospitalist Highland Hospital Disclosures: None -
Today we'll focus on a major shift in the treatment of myasthenia gravis -- as a wave of new therapies is changing how we treat this disease. Who should be considered for these new treatments? And what else is in the pipeline?
Our guest today is Dr. Gil Wolfe, a neuromuscular neurologist at the University of Buffalo State University of New York, Jacob School of Medicine and Biomedical Sciences. Dr. Wolfe was interviewed by Dr. Ioannis Karakis, adjunct professor of neurology at Emory University School of Medicine.
References:
https://www.nature.com/articles/s41598-024-79918-7
Disclosures: Dr. Wolfe discloses: Consultant for: Alexion, Argenx, BPL, Cartesian, Canopy, Grifols, Johnson & Johnson, Takeda, UCB; Speaker Bureau for: Grifols, Alexion, UCB; Grant/Research support from: ArgenX, Ra/UCB, Immunovant, Roche, Alexion, Sanofi
-
Climate change is no longer a distant worry—it's showing up in neurology clinics across the US, from Lyme meningitis in the Midwest to worsening migraines during heat waves, climate-linked and vector-borne neurological conditions are entering the differential.
Our guests today are two experts on climate change and neurological health: Dr. Beth Malow, Professor of Neurology and Pediatrics at Vanderbilt University Medical Center, and Dr. Monica Diaz, Assistant Professor of Neurology at the University of North Carolina at Chapel Hill. They'll explore the clinical impact of climate change on neurology, and how neurologists can adapt through patient care, advocacy, and research.
Drs. Malow and Diaz were interviewed by Dr. Sara Stern-Nezer, Associate Professor of Neurology at the University of California, Irvine.
Interviewer: Dr. Sara Stern-Nezer, Associate Professor of Neurology at the University of California, Irvine Guests: Dr. Beth Ann Malow, Professor of Neurology and Pediatrics at Vanderbilt University Medical Center, and Dr. Monica Diaz, Assistant Professor of Neurology at the University of North Carolina at Chapel Hill Disclosure: Dr. Malow serves as a consultant for Neurim Pharmaceuticals. Resources: Neurologists Interested in Climate and Health (NICHE) Climate Change and Brain Health: What Do We Know and What Can We Do? http://nichebrainhealth.com/what-we-can-do/ -
Restless leg syndrome is a common movement and sleep disorder affecting 2-3% of the population. Certain neurologic disorders are associated with a higher incidence, and neuropsychiatric medications prescribed by neurologists and psychiatrists often exacerbate these symptoms. In January, the American Academy of Sleep Medicine published updated guidelines for the evaluation and treatment of RLS. The recommendations shifted from recommending the use of dopamine agonists, to prioritizing iron evaluation and supplementation, alpha-2-delta ligands (gabapentin, gabapentin enacarbil, pregabalin), and recommending against the long-term use of dopamine agonists. The guidelines also recommend opiates for moderate-severe medication refractory RLS. Dr. Winkleman is a Professor of Psychiatry at Harvard Medical School and chief of the Sleep Disorders Clinical Research Program in the Department of Psychiatry at Massachusetts General Hospital. He is the first-author on the new guidelines, and is here to discuss these changes and what is needed to effectively change practice. He is interviewed by Dr. Kara Wyant, Clinical Assistant Professor of Neurology, University of Michigan Medical School. RLS Curbside
-
Look around you right now and think for a minute about all of the things you're exposed to: the coffee you're drinking, the mug holding the coffee you're drinking, the soap that mug was washed in, the sleep you got last night -- or didn't get. All of this is part of what we now call your exposome. And as we're learning, the neural exposome influences our risk of developing a range of neurologic diseases.
Our guest today is Dr. Eva Feldman, the James W Albers Distinguished University Professor and the Russell N. De Young professor of neurology and neurosurgery at the University of Michigan. She'll talk to us about research on the neural exposome in neurodegenerative disease -- and what we should be telling patients and policymakers about this research. Dr. Feldman was interviewed by Dr. Vinita Acharya, Professor of Neurology and Distinguished Educator at Penn State College of Medicine.
Guest: Dr. Eva Feldman, the James W Albers Distinguished University Professor and the Russell N. De Young professor of neurology and neurosurgery at the University of Michigan - https://medicine.umich.edu/dept/mni/eva-feldman-md-phd Interviewer: Dr. Vinita Acharya, Professor of Neurology and Distinguished Educator at Penn State College of Medicine Disclosures: None -
Neurologists bring an important perspective to health policy. But few have formal training in how to advocate for patients at a state or national level. Our guest today, Dr. Kara Stavros, is an associate professor of neurology at The Warren Alpert Medical School of Brown University and the President of the Rhode Island Medical Society. She's also a self-described advocate, who's found a number of ways to speak up for her patients and influence health policy. Dr. Stavros spoke about her path to advocacy with Dr. Sarah Nelson, Assistant Professor of Neurology at Tufts Medical Center.
Guest: Dr. Kara Stavros, associate professor of neurology at The Warren Alpert Medical School of Brown University and the President of the Rhode Island Medical Society Interviewer: Dr. Sarah Nelson, Assistant Professor of Neurology at Tufts Medical Center Disclosures: None -
Parkinson's Disease has long been a clinical diagnosis. But recently, there have been proposals to redefine the disease based on biomarkers of alpha-synucleinopathy and dopaminergic dysfunction. A similar shift has already occurred in Alzheimer disease, with the "amyloid, tau, and neurodegeneration," or ATN, classification system.
Our guest today, Michael Okun, is is Professor of Neurology and Director of the Norman Fixel Institute for Neurological Diseases at the University of Florida and medical advisor for the Parkinson's Foundation. He co-authored an op-ed in JAMA last summer in JAMA arguing that there would be benefits to a biological definition of Parkinson's - but there would also be risks. He'll unpack both sides of this debate today with Dr. Christine Doss Esper, Associate Professor of Neurology at Emory University. Series 6, Episode 5
Featuring:
Guest: Dr. Michael Okun, is Professor of Neurology and Director of the Norman Fixel Institute for Neurological Diseases at the University of Florida and medical advisor for the Parkinson's Foundation Interviewer: Dr. Christine Doss Esper, Associate Professor of Neurology at Emory University Disclosures: None -
We all know that atrial fibrillation is associated with increased risk of stroke. But new research suggests that how we define afib -- and the timing and duration of the arrhythmia -- may be important for how we manage it in stroke patients. Luciano Sposato is a Professor of Neurology and Head of the Stroke Program at Western University in Ontario. He'll talk to Christoph Stretz, vascular neurologist at Brown University, about the latest research into afib and aflutter after stroke -- and how this research might impact current clinical practice. Series 6, Episode 4
Featuring: Guest: Dr. Luciano Sposato, Professor of Neurology and Head of the Stroke Program at Western University in Ontario & Interviewer: Christoph Stretz, vascular neurologist at Brown University
Disclosures: Dr. Sposato disclosed consulting fees and honoraria from Bayer, Boehringer Ingelheim, Pfizer, Gore, Astrazeneca, and Simcere.
-
Dementia is a global issue, with two-thirds of people with dementia living in low- and middle- income countries. Despite this, dementia research continues to focus on patients in high-income countries. Our guest on this episode, Dr. Riadh Gouider, is working to correct this imbalance. Dr. Gouider is the Head of the Department of Neurology and the Alzheimer Center at Razi Hospital in Tunisia and an advisor on the latest WHO Global Action Plan on the public health response to dementia. He spoke with Dr. Jayant Acharya, Professor and Chair of Neurology at Southern Illinois University School of Medicine -- about challenges, and opportunities, for dementia research across the globe. Series 6, Episode 3
Featuring: Dr. Riadh Gouider, Head of the Department of Neurology and the Alzheimer Center at Razi Hospital in Tunisia & Dr. Jayant Acharya, Professor and Chair of Neurology at Southern Illinois University School of Medicine.
Disclosures: NoneBelow are the links to the publications discussed during this episode.
Lancet Commission on Dementia: https://www.thelancet.com/commissions/dementia-prevention-intervention-care WHO Global Action Plan on Dementia: https://www.who.int/publications/i/item/global-action-plan-on-the-public-health-response-to-dementia-2017---2025 -
It used to be that surgery for medically refractory epilepsy was big, open and invasive, a treatment of last resort. The landscape has changed in recent decades, with more and more minimally invasive surgical approaches being developed. So what does this mean for the average patient with medically refractory epilepsy? Our guest today is Dr. Jon Willie, Associate Professor, Department of Neurological Surgery, Washington University School of Medicine in St. Louis. He speaks with Dr. Ionnis Karakis, Epileptologist and Adjunct Professor of Neurology at Emory University, about the new landscape of epilepsy surgery. Series 6, Episode 2
Featuring:
Guest: Jon T. Willie, MD, PhD, FAANS, Associate Professor, Department of Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri Interviewer: Ioannis Karakis, MD, PhD, MSc., Epileptologist and Adjunct Professor of Neurology at Emory UniversityDisclosures: Dr. Karakis disclosed that he is a consultant for USB, GSK, Ceribell, and Epitel. Dr. Willie disclosed Consulting for Clearpoint, Inc, AiM Medical Robotics, Inc., and Fortec Medical, Inc.; Contracted Research with Abbott, Inc., Neurona, Inc., and Neuropace, Inc.; and Honoraria from Medtronic, Inc.
-
Until recently, the Glymphatic System was a neglected corner of neuroscience. Now it's increasingly clear that the brain's system for the flow of fluid, nutrients, and waste plays an important role in sleep and brain disease. With glymphatics in the spotlight, researchers are coming up with innovative ways to study this slow, constant flow of cerebrospinal fluid throughout the brain. Dr. Daniel Claassen is a Professor of Neurology and Chief of the Behavioral and Cognitive Neurology Division at Vanderbilt University, who researches the glymphatic system in humans. He'll talk about new directions in glymphatics research with Dr. Cheran Elangovan, a Vascular Neurologist at the University of Tennessee Health Science Center. Series 6, Episode 1
Featuring:
Guest: Dr. Daniel Claassen is a Professor of Neurology and Chief of the Behavioral and Cognitive Neurology Division at Vanderbilt University Interviewer: Dr. Cheran Elangovan, a Vascular Neurologist at the University of Tennessee Health Science Center Disclosures: No relationships - Laat meer zien
